Guidance

Monkeypox vaccination recommendations

Recommendations for the use of pre and post exposure vaccination during a monkeypox incident.

From:
UK Health Security Agency
Published
20 May 2022
Last updated
522 August 2022 — See all updates

Applies to England

Documents

Recommendations for the use of pre and post exposure vaccination during a monkeypox incident

Ref: UKHSA gateway number GOV-12970GOV-13059 PDF, 363825 KB, 3640 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This document includes information on:

  • pre-exposure vaccination for occupational exposure
  • post-exposure vaccination
  • vaccine prescribing and administration
  • consent and record forms
  • Imvanex® patient information leaflet

Further monkeypox guidance is also available, including information on case definitions and contact tracing.

Published 20 May 2022
Last updated 522 August 2022 + show all updates

  1. Updated to include the use of intradermal administration for pre and post-exposure use in healthy adults, limiting post-exposure vaccination to children under 5 and immunosuppressed individuals, during periods of limited supply, and further clarification on vaccine eligibility for occupational exposure.

  2. Updated guidance, version 10.

  3. Version 9: updated background and added a link to classification of contacts (appendix 6), along with advice for vaccination and follow-up.

  4. Updated appendix 6 to clarify recommendations for PEP after 14 days since last exposure.

  5. Updated guidance, version 7.

  6. Updated guidance, version 6.7.

  7. Added links to additional monkeypox guidance.

  8. First published.